Predictors of Pregnancy Rate in Assisted Reproductive Technology According to Actual Guidelines

Inclusion Criteria:

• Female, age ≥ 18 years
• Prescribed Duphaston® according local marketing authorization and international andRussian In Vitro Fertilisation guidelines for luteal phase support as part of anAssisted Reproductive Technologies (1 tablet 3 times a day starting at the day ofoocyte retrieval)
• Elective single embryo transfer in fresh cycle
• Normal ultrasound at enrollment without evidence of clinically significant abnormalityconsistent with finding adequate for Assisted Reproductive Technologies with respectto uterus and adnexa (incl. no hydrosalpinx or clinically relevant uterine fibroids)
• Signed the Patient Authorization for Use/Disclosure of Data

Exclusion Criteria:

• Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic,hematologic/immunologic, HEENT (head, ears, eyes, nose, throat),dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine,neurologic/psychiatric, allergy, recent major surgery (< 3 months), or other relevantdiseases as revealed by history, physical examination and/or laboratory assessmentswhich could limit participation in or completion of the study
• Acute urogenital disease
• Known allergic reactions to dydrogesterone or other progestogens products
• Any contraindication or other condition that precludes use of dydrogesterone in aparticular patient, in accordance with the precautions listed in the locally approvedlabel (Instructions for the medical use of Duphaston®):
• Hypersensitivity to dydrogesterone or any of the excipients
• Diagnosed or suspected progestogen-dependent neoplasms (e.g., meningioma)
• Undiagnosed vaginal bleeding
• Hepatic impairment associated with acute or chronic, current or past liver diseases (as long as liver function tests have failed to return to normal)
• Presence or history of malignant liver tumors
• Galactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome
• Breastfeeding.
• Presence or history of porphyria
• Age below 18 years, since safety and efficacy in adolescents aged below 18 years havenot been established
• Spontaneous abortion (miscarriage) or missed abortion in luteal-phase support as partof assisted reproductive technology
• Participation in any other clinical trial within 30 days prior to program start
• Mental disability or any other lack of fitness, in the Investigator's opinion, topreclude subjects in or to complete the study
• Current or recent substance abuse, including alcohol and tobacco (Note: Patients whostopped tobacco usage at least 3 months prior to screening visit would be allowed)
• History of prior chemotherapy
• Usage of other progestogens except dydrogesterone
• Contraindication for pregnancy
• Refusal or inability to comply with the conditions of this program for any reason,including scheduled clinic visits and laboratory tests.
• Gestational surrogacy, oocyte or embryo donation